Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3207-3214

  Desmedt, Christine ^a   Piette, Fanny ^b   Loi, Sherene ^j   Wang, Yixin ^c   Lallemand, Françoise ^a   Haibe Kains, Benjamin ^a,b   Viale, Giuseppe ^d   Delorenzi, Mauro ^e   Zhang, Yi ^c   D'Assignies, Mahasti Saghatchian ^f   Bergh, Jonas ^g   Lidereau, Rosette ^h   Ellis, Paul ⁱ   Harris, Adrian L ^j   Klijn, Jan G M ^k   Foekens, John A ^k   Cardoso, Fatima ^a   Piccart, Martine J ^a   Buyse, Marc ^b   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g KAROLINSKA INSTITUTE   (Sweden)

^h INSERM   (France)

ⁱ GUY S HOSPITAL   (United Kingdom)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL STUDY; COMPARATIVE STUDY; GENE; GENE EXPRESSION; GENOMICS; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SAMPLE; TIME; VALIDATION STUDY;

EID: 34250652449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2765     Document Type: Article

References (18)

1. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
2. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
3. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
4. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-71.
5. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
6. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
7. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
8. Ravdin PM, Siminoff IA, Harvey JA. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
9. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! For early breast cancer. J Clin Oncol 2005;23:2716-25.
10. Klijn JGM, Wang Y, Atkins D, Foekens JA. Prediction of cancer outcome with microarrays. Lancet 2005;365:1686.
11. Desmedt C, Piette F, Cardoso F, et al. TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer. Late Breaking News Abstract: Fifth European Breast Cancer Conference, Nice, France, March 21-24, 2006.
12. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
13. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci US A 2003;100:7737-42.
14. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
15. Durbecq V, Di Leo A, Cardoso F, et al. Comparison of topoisomerase- IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77:199-204.
16. Poelman SM, Heimann R, Fleming GF, Recant WM, Conzen SD. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer 2004;40:28-32.
17. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-9.
18. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005;65:9155-8.